# Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis

> **NCT03736161** · PHASE3 · COMPLETED · sponsor: **Globe Pharmaceuticals Limited** · enrollment: 61 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Group A- Tofacitinib
- **DRUG:** Group B- Methotrexate

## Key facts

- **NCT ID:** NCT03736161
- **Lead sponsor:** Globe Pharmaceuticals Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-15
- **Primary completion:** 2019-09-28
- **Final completion:** 2019-09-28
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2019-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03736161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03736161, "Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03736161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*